PPP1R1B and neoplasm: Cytoplasmic expression of DARPP-32 remained significantly associated with adverse survival (HR: 0.744; 95% CI: 0.577–0.960; P = 0.023) when the potentially confounding factors were included in multivariate assessment (including tumour size, stage, grade, NPI status, vascular invasion status ER, PgR and HER2 receptor status (all with log rank statistics of P = 0.001).